Navigation Links
Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group
Date:12/29/2008

ime on its promises to customers anywhere in the world. While it is somewhat flattering to see other companies try to learn from CytoCare(TM), we are obviously not going to permit it. We have also begun to see Health Robotics' emerging dominance in the area of non-hazardous IV Admixtures after the i.v.STATION(TM) global installation kick-off at ASHP Mid-Year Meeting in Orlando, by logging in excess of 800 future purchase orders for i.v.STATION(TM) within 6 months of its announcement, more than 25 times the total 10+ year sales volume of all our competitor's non-hazardous IV Robots combined," stated Werner Rainer, CEO of Health Robotics.

About the Devon International Group

The Devon International Group (DIG) is a multi-national group of companies headquartered in King of Prussia, Pennsylvania, spanning the healthcare, information technology, and international business industries. Its flagship companies includes Devon Health Services, a national healthcare cost management company and the largest privately held Preferred Provider Organization (PPO) in the Northeast U.S., Devon IT, the world's third largest manufacturer of thin clients, Devon Medical, and Devon Robotics. In addition to its headquarters and other USA-based office locations, Devon International Group has offices in Dublin (Ireland), London, Lithuania, Bangalore, Shanghai, and Beijing.

About Health Robotics:

Health Robotics is the global leading supplier of life-critical intra-venous medication preparation, compounding, and dispensing Robots, providing health care facilities around the world with robotic technology and software automation solutions. The world-leading solutions CytoCare(TM) [hazardous IVs] and i.v.STATION(TM) [non-hazardous IVs] have and will greatly contribute to ease global hospitals' & clinics' growing pressures to improve patient safety through effective and efficient production of sterile, safe, accura
'/>"/>

SOURCE Health Robotics SRL
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... NEW YORK, Dec. 2 Nearly 600 medical research ... explore novel development approaches and innovative funding strategies at ... ,, FasterCures, the Washington-based center of the ... facilitate multi-sector collaborations needed to turn a scientific discovery ...
(Date:12/2/2009)... , - "Bolstering ... Coinciding with the International ... is hosting an international conference in Libreville,(Gabon) on ... The,conference will be attended by government and state ...
(Date:12/2/2009)... announced data presentations on its novel oral JAK2 inhibitor, ... Meeting and Exposition in New Orleans. ,, Data will ... 1 dose-escalation trial of SB1518 detailing its safety, tolerability ... 100 to 600 mg. These doses were administered once ...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going ... part of many,businesses and industries. It turns out that ... downturn, because illness doesn,t take a,vacation. , ... this year, the pharmaceutical,giant Johnson & Johnson inaugurated an ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the Thomas,Weisel Partners ... Four,Seasons Hotel in Boston. SuperGen,s presentation at ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) a biopharmaceutical ... candidates for the treatment,of cancer and infectious diseases, ... officer, is scheduled to present at the 2007,Thomas ... at 1:30 p.m. Eastern Daylight Time. The conference ...
... 28 DOV Pharmaceutical,Inc. ("DOV" or the "Company") (OTC ... common stock is now being quoted on the OTC,Bulletin ... also still,being quoted on the Pink Sheets. "We ... now being quoted,both on the OTC Bulletin Board and ...
Other Biology Technology:ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference 2DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board 2
(Date:12/4/2009)... CORVALLIS, Ore. According to an analysis of statewide ... less than $50,000 a year were more than three ... health providers because of their insurance status during pregnancy ... discrimination was also three times more likely among mothers ...
(Date:12/4/2009)... Royal Botanic Gardens, Kew and the Natural History Museum ... widespread than previously thought, with many commonly grown plants ... to being "meat eaters". A review paper, Murderous plants: ... is published today (4 December 2009) in the ...
(Date:12/4/2009)... is available in German . , A ... Ageing could help to understand the positive effect of dietary ... flies and mice) have shown that dietary restriction increases longevity, ... So the female fruit fly reproduces less frequently with a ...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8
... responsible for the single most common cause of hearing ... the first time, a scientist told the annual conference ... France. Ms Melissa Thys, from the Department of Medical ... may be a step towards new treatments for otosclerosis, ...
... nanoparticle made in a laboratory at the University of ... device for treating glaucoma, an eye disease that can ... “The nanoparticle can safely get past the blood-brain barrier ... said Sudipta Seal, an engineering professor with appointments in ...
... announced this week the discovery of a mechanism by ... in serious lung infections and is prevalent in emphysema ... or “macrophages” and thus compromises the body’s immunity. , ... State University, will be published online this week in ...
Other Biology News:Gene responsible for common hearing loss identified for first time 2UCF nanoparticle offers promise for treating glaucoma 2Researchers discover 'acquired' DNA key to certain bacterial infection 2
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... This depletion cocktail is ... (CD3+CD4+CD8+) cells from suspensions of ... Cells are separated using the ... immunomagnetic negative selection system, achieving ...
...
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... selection system. The CD4+ T ...
Biology Products: